Tuesday, October 21, 2014

Analysts launch coverage of Tokai Pharma

Analysts launch coverage of Tokai Pharma

October 13, 2014 by · Leave a Comment 

Tweet Analysts at William Blair, Stifel and Janney Capital Markets initiated coverage of Tokai Pharmaceuticals (NASDAQ:TKAI), saying its lead asset, galeterone, represents a first-in-class and best-in-class, selective and multi-targeted small molecule that should offer advantages over existing prostate cancer therapies. Analyst Katherine Xu started Tokai at “outperform” with a $44 price target. Shares of Tokai […]

Jefferies starts ReWalk Robotics at buy

Jefferies starts ReWalk Robotics at buy

October 7, 2014 by · Leave a Comment 

Tweet Jefferies has initiated coverage of ReWalk Robotics (NASDAQ:RWLK) with a “buy” rating and price target of $39. The stock closed at $29.20 on Monday. ReWalk is a leader in the development and commercialization of robotic Exoskeletons, mechanical devices that aid in mobility and other physical functions, allowing spinal cord injured patients to stand and walk. “With […]

Verisante begins FDA approval process for Aura

Verisante begins FDA approval process for Aura

October 1, 2014 by · Leave a Comment 

Tweet Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has initiated communications with the FDA for the approval of Aura, a device for the detection of skin cancer. “Verisante has now submitted documents to the FDA as we begin the formal application process for approval to market and sell Aura in the U.S.,” president and CEO, Thomas Braun, said […]

Amarantus requests pre-IND feedback from FDA

Amarantus requests pre-IND feedback from FDA

September 29, 2014 by · Leave a Comment 

Tweet Amarantus Bioscience Holdings (OTCQB:AMBS) has submitted a request to the FDA for a review and written feedback of the Phase 2b clinical trial design for Eltoprazine in levodopa-induced dyskinesia (LID), a common side effect of levodopa treatment in Parkinson’s disease patients. ”We are very pleased to have submitted this pre-IND review request letter to […]

Mackie Research starts Medicure at buy

Mackie Research starts Medicure at buy

September 26, 2014 by · Leave a Comment 

Tweet Mackie Research has initiated coverage of Medicure (TSX-V:MPH) with a “buy” recommendation and 12-month target price of $2.80. The stock was quoted at $2.10 on Friday morning. “The FDA approval of Aggrastat HDB in October 2013 and its launch should be the driver of sales and earnings,” writes analyst Andre Uddin. He expects revenue […]

Amarantus on road to commercializing AD test

Amarantus on road to commercializing AD test

September 23, 2014 by · Leave a Comment 

Tweet Amarantus Bioscience Holdings’ (OTCQB:AMBS) master services agreement with the lab services arm of ICON (NASDAQ:ICLR) puts Amarantus on the road to commercializing its LymPro diagnostic blood test for the early detection of Alzheimer’s disease (AD). “This agreement represents a major milestone, as we can now prepare LymPro for launch with a top-tier commercial development […]

Continuum of care to drive future NOVADAQ imaging growth

Continuum of care to drive future NOVADAQ imaging growth

September 9, 2014 by · Leave a Comment 

Tweet NOVADAQ Technologies (NASDAQ:NVDQ; TSX:NDQ), pioneers in fluorescence imaging solutions for the operating room, is now focused on manufacturing and directly marketing and selling imaging solutions for use at multiple points throughout the patient care continuum. “Our continuum of care includes diagnostics that can be performed at outpatient clinics and by primary care physicians, where […]

Feltl starts Tandem Diabetes with strong buy

Feltl starts Tandem Diabetes with strong buy

September 4, 2014 by · Leave a Comment 

Tweet Feltl & Co. has initiated coverage of Tandem Diabetes Care (NASDAQ:TNDM) with a “strong buy” rating and $19 price target. The stock closed at $14.36 on Thursday. “Tandem Diabetes entered the pump market with the t:slim in late 2012 and is gaining traction with both diabetics utilizing multiple daily injections (MDI) to deliver insulin, […]

Alitair gets second U.S. patent on ion exchange resin

Alitair gets second U.S. patent on ion exchange resin

September 4, 2014 by · Leave a Comment 

Tweet Closely-held Alitair Pharmaceuticals has received a second patent from the U.S. Patent and Trademark Office for its ion exchange resin formulation of benzonatate, benzonatate polacrilex. The new patent contains a composition of matter claim, covering the use of Alitair’s ion exchange formulation of benzonatate. The new patent also contains claims for using benzonatate polacrilex […]

Dipexium aims to have first topical antibiotic approved for DFI

Dipexium aims to have first topical antibiotic approved for DFI

September 2, 2014 by · Leave a Comment 

Tweet Dipexium (NASDAQ:DPRX) is enrolling patients in two pivotal Phase 3 trials of its Locilex topical antibiotic in what it hopes will be the first FDA-approved antibiotic topical cream for the treatment of mild infections of diabetic foot ulcers. “Current treatments used off-label to treat mild diabetic foot infections (DFI) generate systemic resistance, exhibit poor […]

Next Page »

Email Newsletters with Constant Contact
Google+